CompletedNot Applicable

Antibiotic Resistance of Helicobacter Pylori in Nanjing: A Cross-Sectional Study

China7,227 participantsStarted 2026-03-01

Plain-language summary

This study aims to provide an updated analysis of the resistance patterns of H. pylori in the Nanjing region, with a focus on characterizing the current status of phenotypic and genotypic resistance to these six antimicrobial agents. The findings are expected to offer a scientific basis for the rapid diagnosis and personalized treatment of H. pylori infection.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients who visited the Gastroenterology Department of Nanjing First Hospital and underwent gastroscopy with H. pylori culture and genetic testing between 2018 and 2024.
✓. Positive for H. pylori by at least one diagnostic method (13C-urea breath test, rapid urease test, or histopathology).
✓. Provision of general written informed consent for the use of gastroscopy and specimen data in research.
✓. Availability of complete medical records and laboratory test results.

Exclusion criteria

✕. Withdrawal of informed consent; use of antibiotics, proton pump inhibitors, H2-receptor antagonists, or bismuth agents within four weeks prior to gastroscopy.
✕. History of gastric surgery.
✕. Incomplete medical records or test results precluding evaluation.
✕. Other factors deemed by the investigator to render the participant unsuitable for inclusion.

What they're measuring

Phenotypic Antibiotic Resistance Rate

Timeframe: April to May 2026

Trial details

NCT IDNCT07455448

SponsorNanjing First Hospital, Nanjing Medical University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-03-25

View on ClinicalTrials.gov More HELICOBACTER PYLORI INFECTIONS trials